FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023597204> ?p ?o ?g. }

• W2023597204 endingPage "29" @default.
• W2023597204 startingPage "23" @default.
• W2023597204 abstract "ObjectiveThe aim of the study was to evaluate the effect of azithromycin on the expansion rate of small abdominal aortic aneurysms (AAAs), and to determine whether or not a correlation exists between serological markers for Chlamydophilia pneumonia (Cpn) infection and AAA expansion.MethodsNine vascular centers were included and 259 patients were invited to participate. Ten patients declined and 2 patients had chronic kidney failure, leaving a total of 247 patients. Inclusion criteria were: AAA 35-49 mm and age <80 years. Patients were randomized to receive either azithromycin (Azithromax, Pfizer Inc, New York, NY) 600 mg once daily for 3 days and then 600 mg once weekly for 15 weeks, or placebo in identical tablets. The ultrasound scans were performed in a standardized way within a month before inclusion and every 6 months for a minimum follow-up time of 18 months. Cpn serology was analyzed in blood samples taken at inclusion and 6 months later. Serum was analyzed for Cpn IgA and IgG antibodies by microimmunofluorescence (MIF). Computed tomography (CT) scans were done in 66 patients at inclusion and at 1 year for volume calculations.ResultsThirty-four patients were excluded, ie, could not be followed for 18 months, 20 in the placebo group and 16 in the active treatment group. A total of 211 patients had at least two measurements and all were analyzed in an intention-to-treat analysis. Detectable IgA against Cpn was found in 115 patients and detectable IgG against Cpn in 160 patients. No statistically significant differences were found between the groups regarding median expansion rate measured by ultrasound scan (0.22 cm/year, interquartile range [IQR]: 0.09 to 0.34 in the placebo group vs 0.22, IQR: 0.12 to 0.36 in the treatment group, P = .85). Volume calculation did not change that outcome (10.4 cm3/year in the placebo group vs 15.9 cm3/year in the treatment group, P = .61). No correlation was found between serological markers for Cpn infection and the expansion rate. Patients taking statins in combination with acetylsalicylic acid (ASA) had significantly reduced expansion rate compared to patients who did not take statins or ASA, 0.14 cm/year vs 0.27 cm/year, P < .001.ConclusionAzithromycin did not have any effect on AAA expansion. No correlation was found between serological markers for Cpn and AAA expansion, indicating no clinical relevance for Cpn testing in AAA surveillance. However, a significant reduction in AAA expansion rate was found in patients treated with a combination of ASA and statins. The aim of the study was to evaluate the effect of azithromycin on the expansion rate of small abdominal aortic aneurysms (AAAs), and to determine whether or not a correlation exists between serological markers for Chlamydophilia pneumonia (Cpn) infection and AAA expansion. Nine vascular centers were included and 259 patients were invited to participate. Ten patients declined and 2 patients had chronic kidney failure, leaving a total of 247 patients. Inclusion criteria were: AAA 35-49 mm and age <80 years. Patients were randomized to receive either azithromycin (Azithromax, Pfizer Inc, New York, NY) 600 mg once daily for 3 days and then 600 mg once weekly for 15 weeks, or placebo in identical tablets. The ultrasound scans were performed in a standardized way within a month before inclusion and every 6 months for a minimum follow-up time of 18 months. Cpn serology was analyzed in blood samples taken at inclusion and 6 months later. Serum was analyzed for Cpn IgA and IgG antibodies by microimmunofluorescence (MIF). Computed tomography (CT) scans were done in 66 patients at inclusion and at 1 year for volume calculations. Thirty-four patients were excluded, ie, could not be followed for 18 months, 20 in the placebo group and 16 in the active treatment group. A total of 211 patients had at least two measurements and all were analyzed in an intention-to-treat analysis. Detectable IgA against Cpn was found in 115 patients and detectable IgG against Cpn in 160 patients. No statistically significant differences were found between the groups regarding median expansion rate measured by ultrasound scan (0.22 cm/year, interquartile range [IQR]: 0.09 to 0.34 in the placebo group vs 0.22, IQR: 0.12 to 0.36 in the treatment group, P = .85). Volume calculation did not change that outcome (10.4 cm3/year in the placebo group vs 15.9 cm3/year in the treatment group, P = .61). No correlation was found between serological markers for Cpn infection and the expansion rate. Patients taking statins in combination with acetylsalicylic acid (ASA) had significantly reduced expansion rate compared to patients who did not take statins or ASA, 0.14 cm/year vs 0.27 cm/year, P < .001. Azithromycin did not have any effect on AAA expansion. No correlation was found between serological markers for Cpn and AAA expansion, indicating no clinical relevance for Cpn testing in AAA surveillance. However, a significant reduction in AAA expansion rate was found in patients treated with a combination of ASA and statins." @default.
• W2023597204 created "2016-06-24" @default.
• W2023597204 creator A5013259507 @default.
• W2023597204 creator A5030629924 @default.
• W2023597204 creator A5054031425 @default.
• W2023597204 creator A5056206844 @default.
• W2023597204 creator A5069913131 @default.
• W2023597204 date "2009-07-01" @default.
• W2023597204 modified "2023-10-17" @default.
• W2023597204 title "The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms - A prospective randomized double-blind trial" @default.
• W2023597204 cites W1826304360 @default.
• W2023597204 cites W1976019589 @default.
• W2023597204 cites W1991417567 @default.
• W2023597204 cites W1993285295 @default.
• W2023597204 cites W2011428701 @default.
• W2023597204 cites W2013720516 @default.
• W2023597204 cites W2017524691 @default.
• W2023597204 cites W2019129848 @default.
• W2023597204 cites W2030949712 @default.
• W2023597204 cites W2046713846 @default.
• W2023597204 cites W2051489484 @default.
• W2023597204 cites W2054216018 @default.
• W2023597204 cites W2062425226 @default.
• W2023597204 cites W2065179652 @default.
• W2023597204 cites W2068284042 @default.
• W2023597204 cites W2076627186 @default.
• W2023597204 cites W2085143721 @default.
• W2023597204 cites W2113675263 @default.
• W2023597204 cites W2119005170 @default.
• W2023597204 cites W2120149146 @default.
• W2023597204 cites W2122876953 @default.
• W2023597204 cites W2133689300 @default.
• W2023597204 cites W2135742242 @default.
• W2023597204 cites W2146723903 @default.
• W2023597204 cites W2147433381 @default.
• W2023597204 cites W2150974492 @default.
• W2023597204 cites W2153107010 @default.
• W2023597204 cites W2153219551 @default.
• W2023597204 cites W2154244638 @default.
• W2023597204 cites W2155807420 @default.
• W2023597204 cites W2162134373 @default.
• W2023597204 cites W2163790696 @default.
• W2023597204 cites W2575806582 @default.
• W2023597204 cites W4231266888 @default.
• W2023597204 cites W99975987 @default.
• W2023597204 doi "https://doi.org/10.1016/j.jvs.2008.12.048" @default.
• W2023597204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19563951" @default.
• W2023597204 hasPublicationYear "2009" @default.
• W2023597204 type Work @default.
• W2023597204 sameAs 2023597204 @default.
• W2023597204 citedByCount "82" @default.
• W2023597204 countsByYear W20235972042012 @default.
• W2023597204 countsByYear W20235972042013 @default.
• W2023597204 countsByYear W20235972042014 @default.
• W2023597204 countsByYear W20235972042015 @default.
• W2023597204 countsByYear W20235972042016 @default.
• W2023597204 countsByYear W20235972042017 @default.
• W2023597204 countsByYear W20235972042018 @default.
• W2023597204 countsByYear W20235972042019 @default.
• W2023597204 countsByYear W20235972042020 @default.
• W2023597204 countsByYear W20235972042021 @default.
• W2023597204 countsByYear W20235972042022 @default.
• W2023597204 countsByYear W20235972042023 @default.
• W2023597204 crossrefType "journal-article" @default.
• W2023597204 hasAuthorship W2023597204A5013259507 @default.
• W2023597204 hasAuthorship W2023597204A5030629924 @default.
• W2023597204 hasAuthorship W2023597204A5054031425 @default.
• W2023597204 hasAuthorship W2023597204A5056206844 @default.
• W2023597204 hasAuthorship W2023597204A5069913131 @default.
• W2023597204 hasBestOaLocation W20235972041 @default.
• W2023597204 hasConcept C126322002 @default.
• W2023597204 hasConcept C141071460 @default.
• W2023597204 hasConcept C142724271 @default.
• W2023597204 hasConcept C159654299 @default.
• W2023597204 hasConcept C168563851 @default.
• W2023597204 hasConcept C188816634 @default.
• W2023597204 hasConcept C203014093 @default.
• W2023597204 hasConcept C204787440 @default.
• W2023597204 hasConcept C27081682 @default.
• W2023597204 hasConcept C2777914695 @default.
• W2023597204 hasConcept C2778907293 @default.
• W2023597204 hasConcept C45189115 @default.
• W2023597204 hasConcept C501593827 @default.
• W2023597204 hasConcept C71924100 @default.
• W2023597204 hasConcept C86803240 @default.
• W2023597204 hasConcept C89423630 @default.
• W2023597204 hasConcept C90924648 @default.
• W2023597204 hasConceptScore W2023597204C126322002 @default.
• W2023597204 hasConceptScore W2023597204C141071460 @default.
• W2023597204 hasConceptScore W2023597204C142724271 @default.
• W2023597204 hasConceptScore W2023597204C159654299 @default.
• W2023597204 hasConceptScore W2023597204C168563851 @default.
• W2023597204 hasConceptScore W2023597204C188816634 @default.
• W2023597204 hasConceptScore W2023597204C203014093 @default.
• W2023597204 hasConceptScore W2023597204C204787440 @default.
• W2023597204 hasConceptScore W2023597204C27081682 @default.
• W2023597204 hasConceptScore W2023597204C2777914695 @default.
• W2023597204 hasConceptScore W2023597204C2778907293 @default.

• next